KYTX
Kyverna Therapeutics, Inc.NASDAQHealthcare$8.87+1.14%ClosedMarket Cap: $388.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.82
P/S
0.00
EV/EBITDA
-1.85
DCF Value
$2.04
FCF Yield
-39.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-81.4%
ROA
-54.9%
ROIC
-65.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-39.3M | $-37.8M | $-0.80 | — |
| FY 2025 | $0.00 | -Infinity% | $-169.8M | $-161.3M | $-3.64 | — |
| Q3 2025 | $0.00 | -Infinity% | $-38.7M | $-36.8M | $-0.85 | — |
| Q2 2025 | $0.00 | -Infinity% | $-44.4M | $-42.1M | $-0.97 | — |
| Q1 2025 | $0.00 | -Infinity% | $-47.4M | $-44.6M | $-1.03 | — |
| Q4 2024 | $0.00 | -Infinity% | $-41.0M | $-37.5M | $-0.87 | — |
| FY 2024 | $0.00 | -Infinity% | $-142.6M | $-127.5M | $-3.33 | — |
| Q3 2024 | $0.00 | -Infinity% | $-38.8M | $-34.5M | $-0.80 | — |
| Q2 2024 | $0.00 | NaN% | $-33.4M | $-28.8M | $-0.67 | — |
| Q1 2024 | $0.00 | -Infinity% | $-29.4K | $-26.7K | $-1.12 | — |
| Q4 2023 | $0.00 | -Infinity% | $-21.4M | $-20.7M | $-0.48 | — |
| FY 2023 | $0.00 | -Infinity% | $-62.4M | $-60.4M | $-0.00 | — |